Loading...

LPCN LIPOCINE INC Management Changes 8-K Filing

LPCN

LPCN

LIPOCINE INC

(LPCN)

2025 8-K

Corporate Presentation Update

Topline Results Announced

Financial Results Announcement

Stock Offering Plan

Corporate Update

Phase 3 Trial Update

Phase 3 Trial Update

Corporate Presentation Update

Safety Review Update

Enrollment Update

Board Resignation

Research Presentation

Corporate Update

Clinical Trial Update

Quarterly Financial Results

Clinical Data Presentation

Clinical Trial Update

Corporate Update

Investor Conference Announc...

Investor Conference Alert

Conference Announcement

Financial Statements

Presentation Updates

Product Expansion

Investor Meetings

Market Expansion

New Product Launches

Investor Meetings

Corporate Presentations

Financial Statements

Market Expansion

Corporate Update

Trial Announcement

Financial Results

FDA Labeling Changes

Corporate Update

Regulatory Update

Corporate Update

Corporate Update

LPCN 1148 Update

Financial Results

Research Presentation

License Agreement

Stockholder Rights Plan

Positive Study Results

Distribution Agreement

Investor Conference

KOL Event Announcement

Investor Conference

Earnings Release

Amendment Filing

Data Presentation and Press...

Annual General Meeting of S...

Bonus Plan Approval and Ame...

Update of Presentation

Clinical Trial Results

Update of Presentation

Conference Presentation

License Agreement with Gord...

Presentation Update

Investor Conferences

Announcement of Abstract Pr...

FDA Meeting and Study Annou...

Presentation Update

Termination of License Agre...

Conference Presentation

Earnings Reports

Corporate Presentation Update

Presentation at Conference

Data Presentation at Confer...

Conference Presentation

Announcement of Presentatio...

Compliance with Minimum Bid...

Clinical Study Results

Reverse Stock Split

Corporate Presentation Update

Cash Bonus Plan Approval

Regulation FD Disclosure

Material Modification to Ri...

Earnings Reports

Presentation at Biotech Sho...

Update of Presentation

Investor Conferences

External Links:

On November 18, 2025, Lipocine Inc. announced a positive interim safety profile for LPCN 1154 in its Phase 3 clinical trial for postpartum depression (PPD). This is a significant event indicating potential progress in their drug development.

AI Assistant

LIPOCINE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.